Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia

Blood

Volumn 119, Issue 25, 2012, Pages 6025-6031

  Blum, William ^a   Schwind, Sebastian ^a   Tarighat, Somayeh S ^a   Geyer, Susan ^a   Eisfeld, Ann Kathrin ^a   Whitman, Susan ^a   Walker, Alison ^a   Klisovic, Rebecca ^a   Byrd, John C ^a   Santhanam, Ramasamy ^a   Wang, Hongyan ^a   Curfman, John P ^a   Devine, Steven M ^a   Jacob, Samson ^a   Garr, Celia ^a   Kefauver, Cheryl ^a   Perrotti, Danilo ^a   Chan, Kenneth K ^b   Bloomfield, Clara D ^a   Caligiuri, Michael A ^a   Grever, Michael R ^a   Garzon, Ramiro ^a   Marcucci, Guido ^a   more..

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BORTEZOMIB; CD135 ANTIGEN; DNA METHYLTRANSFERASE; HYDROXYUREA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA 29B; PROTEIN TYROSINE KINASE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; BLOODSTREAM INFECTION; CELLULITIS; CLINICAL ARTICLE; CONFUSION; CONTROLLED STUDY; DOWN REGULATION; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG TOLERABILITY; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HEART ATRIUM FIBRILLATION; HUMAN; HUMAN CELL; HYPERGLYCEMIA; LUNG FIBROSIS; LUNG TOXICITY; MALE; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUROTOXICITY; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RASH; REPEATED DRUG DOSE; SYNCOPE; TRANSCRIPTION INITIATION; TREATMENT DURATION; TREATMENT RESPONSE; UPREGULATION;

EID: 84862726260     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-03-413898     Document Type: Article

References (18)

1. Breems DA, Van Putten WL, Huijgens PC, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol. 2005;23(9):1969-1978. (Pubitemid 46211376)
2. Farag SS, Archer KJ, Mrozek K, et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood. 2006;108(1):63-73. (Pubitemid 43996625)
3. Cortes J, Thomas D, Koller C, et al. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res. 2004;10(10):3371-3376. (Pubitemid 38685442)
4. Attar EC, De Angelo DJ, Supko JG, et al. Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. Clin Cancer Res. 2008;14(5):1446-1454. (Pubitemid 351413928)
5. Liu S, Liu Z, Xie Z, et al. Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia. Blood. 2008;111(4):2364-2373. (Pubitemid 351451445)
6. Liu S, Wu LC, Pang J, et al. Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell. 2010;17(4):333-347.
7. Whitman SP, Maharry K, Radmacher MD, et al. FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood. 2010;116(18):3622-3626.
8. Ozeki K, Kiyoi H, Hirose Y, et al. Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. Blood. 2004;103:1901-1908. (Pubitemid 38268989)
9. Masson K, Rönnstrand L. Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3. Cell Signal. 2009;12:1717-1726.
10. Sanz M, Burnett A, Lo-Coco F, Löwenberg B. FLT3 inhibition as a targeted therapy for acute myeloid leukemia. Curr Opin Oncol. 2009;21:594-600.
11. Whitman SP, Ruppert AS, Radmacher MD, et al. FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood. 2008;111:1552-1559. (Pubitemid 351213445)
12. Blum W, Garzon R, Klisovic RB, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A. 2010;107(16):7473-7478.
13. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21(24):4642-4649. (Pubitemid 46594039)
14. Garzon R, Liu S, Fabbri M, et al. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood. 2009;113(25):6411-6418.
15. de Vos S, Goy A, Dakhil SR, et al. Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma. J Clin Oncol. 2009;27:5023-5030.
16. Gerecitano J, Portlock C, Moskowitz C, et al. Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma. Br J Haematol. 2009;146(6):652-655.
17. Hainsworth JD, Spigel DR, Barton J, et al. Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network. Cancer. 2008;113(4):765-771.
18. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12:431-440.